BAYRY Stock Recent News
BAYRY LATEST HEADLINES
OPRT, BAYRY and SHG made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 22, 2025.
BTG, PGR, BAYRY, BCH and LNW have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2025.
Germany's Bayer said on Wednesday that its supervisory board had extended the contract of CEO Bill Anderson until March 31, 2029.
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside. The main risks are ongoing glyphosate litigation and pharma pricing pressures, but current valuation heavily discounts these concerns. Despite crop science headwinds and legacy litigation, core pharma brands and pipeline growth provide a foundation for recovery.
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
BAYRY, INSW and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 10, 2025.
ASTH, LGCY, STM, BAYRY and KD have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2025.
The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by Bayer , according to results from a late-stage trial.